Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD. Li X, et al. Among authors: verbrugge se. J Natl Cancer Inst. 2010 Jul 21;102(14):1069-82. doi: 10.1093/jnci/djq198. Epub 2010 May 26. J Natl Cancer Inst. 2010. PMID: 20505154
Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.
Oerlemans R, Berkers CR, Assaraf YG, Scheffer GL, Peters GJ, Verbrugge SE, Cloos J, Slootstra J, Meloen RH, Shoemaker RH, Dijkmans BAC, Scheper RJ, Ovaa H, Jansen G. Oerlemans R, et al. Among authors: verbrugge se. Invest New Drugs. 2018 Oct;36(5):797-809. doi: 10.1007/s10637-018-0569-x. Epub 2018 Feb 14. Invest New Drugs. 2018. PMID: 29442210 Free PMC article.
Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G. Verbrugge SE, et al. J Pharmacol Exp Ther. 2012 Apr;341(1):174-82. doi: 10.1124/jpet.111.187542. Epub 2012 Jan 10. J Pharmacol Exp Ther. 2012. PMID: 22235146 Clinical Trial.
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.
Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, van der Veer M, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, de Gruijl TD, Jansen G. Verbrugge SE, et al. Exp Hematol Oncol. 2013 Jan 10;2(1):2. doi: 10.1186/2162-3619-2-2. Exp Hematol Oncol. 2013. PMID: 23305345 Free PMC article.
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR.
Verbrugge SE, Al M, Assaraf YG, Kammerer S, Chandrupatla DM, Honeywell R, Musters RP, Giovannetti E, O'Toole T, Scheffer GL, Krige D, de Gruijl TD, Niessen HW, Lems WF, Kramer PA, Scheper RJ, Cloos J, Ossenkoppele GJ, Peters GJ, Jansen G. Verbrugge SE, et al. Oncotarget. 2016 Feb 2;7(5):5240-57. doi: 10.18632/oncotarget.6169. Oncotarget. 2016. PMID: 26496029 Free PMC article.
ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2.
Cillessen SA, Hijmering NJ, Moesbergen LM, Vos W, Verbrugge SE, Jansen G, Visser OJ, Oudejans JJ, Meijer CJ. Cillessen SA, et al. Among authors: verbrugge se. Haematologica. 2015 Sep;100(9):e365-8. doi: 10.3324/haematol.2014.118828. Epub 2015 May 14. Haematologica. 2015. PMID: 25975837 Free PMC article. Clinical Trial. No abstract available.
High susceptibility of c-KIT+CD34+ precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model.
van de Ven R, Verbrugge SE, Reurs AW, Bontkes HJ, Hooijberg E, Jansen G, Scheper RJ, Scheffer GL, de Gruijl TD. van de Ven R, et al. Among authors: verbrugge se. Cancer Immunol Immunother. 2011 Jul;60(7):943-51. doi: 10.1007/s00262-011-1003-9. Epub 2011 Mar 24. Cancer Immunol Immunother. 2011. PMID: 21431918 Free PMC article.
12 results